Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib Combined With Osimertinib in Stage IIIb-IV NSCLC With EGFRm and T790M
NCT04029350Phase 2Unknown
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Jul 2019
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of anlotinib in non-small cell lung cancer (NSCLC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Status: unknown.
02
Drugs
anlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04029350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04029350.